Hope After Failure of New Cholesterol Drug |
| New York Times - Nov 6, 2007 |
Drugs to raise so-called good cholesterol may still have a future despite the widely publicized failure last year of an experimental cholesterol treatment from Pfizer, researchers said Monday at a heart conference here.
Pfizer stopped work on its drug torcetrapib last December after a 15,000-patient clinical trial showed that it raised the risk of death by 59 percent and heart problems by 25 percent. The results were a setback for Pfizer and for doctors who had hoped that torcetrapib and drugs like it would become standard treatments for heart disease.
Had it succeeded, torcetrapib would have been the first in a new class of medicines with great commercial potential — drugs meant to raise the level of HDL cholesterol, the so-called good cholesterol that can help keep arteries clear of plaque.
Read Full Article from New York Times
- Posted: 2007-11-06 09:54:45
| More Stock Investor Place Financial News |
 |
|
|
|
| Stock Investor Place Financial News Archive |
|
|
|
